# US 2019/0314312 A1 · Combination therapy to increase endogenous nitric oxide (no) synthesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314312 A1
- Document ID: US20190314312A1
- Status: Published application
- Kind: A1
- Application number: 16/316,639
- Filed: 2017-07-11
- Published: 2019-10-17
- Earliest claimed: 2016-07-11
- Assignees: Yeda Research and Development Co. Ltd.
- Applicants: Yeda Research and Development Co. Ltd.
- Inventors: Ayelet EREZ; Noa STETTNER
- Web page: https://patentgrep.com/patent/US20190314312A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are uses of a therapeutically effective amount of citrulline for the manufacture of a medicament for treatment of a subject having an inflammatory bowel disease (IBD) and/or colon cancer. Also provided are pharmaceutical compositions comprising a therapeutic effective amount of citrulline and a therapeutically effective amount of a flavonoid for the treatment of an inflammatory bowel disease (IBD) and/or colon cancer and kits comprising same.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of treating inflammatory bowel disease (IBD) and/or colon cancer comprising administering to a subject in need thereof a therapeutically effective amount of citrulline and a therapeutically effective amount of a flavonoid, thereby treating the subject.

### Claim 3

A pharmaceutical composition comprising a therapeutic effective amount of citrulline and a therapeutically effective amount of a flavonoid for the treatment of an inflammatory bowel disease (IBD) and/or colon cancer.

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The method of claim 2, wherein said citrulline is co-administered with a therapeutically effective amount of a flavonoid.

### Claim 6 (depends on 2)

The method of claim 2, wherein said therapeutically effective amount of said citrulline and/or of said flavonoid upregulates the level of nitric oxide in enterocyte cells of the subject.

### Claim 7 (depends on 2)

The method of claim 2, wherein said therapeutically effective amount of said citrulline and/or of said flavonoid upregulates the level of Argininosuccinate Lyase (ASL) in enterocyte cells of the subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein said flavonoid is naturally-occurring flavonoid.

### Claim 9 (depends on 8)

The method of claim 8, wherein said naturally-occurring flavonoid is fisetin.

### Claim 10 (depends on 2)

The method of claim 2, wherein said IBD comprises ulcerative colitis.

### Claim 11 (depends on 2)

The method of claim 2, wherein said IBD comprises Crohn's disease.

### Claim 12 (depends on 2)

The method of claim 2, wherein said disease is colon cancer.

### Claim 13 (depends on 2)

The method of claim 2, further comprising administering to the subject an agent which downregulates Argininosuccinate Lyase (ASL) in immune cells of the subject.

### Claim 14 (depends on 13)

The method claim 13, wherein said immune cells comprise macrophages.

### Claim 15 (depends on 3)

The pharmaceutical composition of claim 3, wherein said flavonoid is fisetin.

### Claim 16 (depends on 3)

The pharmaceutical composition of claim 3, wherein said IBD comprises ulcerative colitis.

### Claim 17 (depends on 3)

The pharmaceutical composition of claim 3, wherein said IBD comprises Crohn's disease.

### Claim 18 (depends on 3)

The pharmaceutical composition of claim 3, wherein said disease is colon cancer.
